Companion Medical wins CE Mark for InPen insulin pen
Companion Medical said yesterday that it won CE Mark approval in the European Union for its InPen smart insulin pen and associated diabetes management smartphone application. The company’s InPen system consists of a smart insulin injection pen that connects with an integrated diabetes management app. Read the whole story on our sister site, Drug Delivery Business News The post Companion Medical wins CE Mark for InPen insulin pen appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - July 20, 2018 Category: Medical Devices Authors: Fink Densford Tags: Diabetes Drug-Device Combinations Regulatory/Compliance Companion Medical Source Type: news

Apidra (Insulin Glulisine [rDNA origin] Inj) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 20, 2018 Category: Drugs & Pharmacology Source Type: news

Is Abbott Losing Share in Key Medtech Markets?
By and large, Abbott Laboratories had a phenomenal second quarter this year – and investors took notice. The company's stock hit its highest point since 1995 on Wednesday after beating Wall Street's quarterly expectations and raising its own outlook for 2018. Abbott, MD+DI's 2017 Medtech Company of the Year, clearly has a lot to celebrate as it continues to show the world what its made of. But at least one medtech analyst noticed that the company appears to have lost market share in cardiac rhythm management (CRM) and neuromodulation. Abbott reported CRM sales of $543 million in the second quarter, representing ...
Source: MDDI - July 18, 2018 Category: Medical Devices Authors: Amanda Pedersen Tags: Business Cardiovascular Source Type: news

Medtronic Pumps Confidence in MiniMed Through Performance Guarantee
Medtronic has been leading the industry in the charge toward value-based care, and its efforts have been paying off in spades, as MD+DI has recently observed. Now, the company has found yet another way to stay ahead of the curve. The company recently launched a new performance guarantee program around its MiniMed 670G insulin pump. The new program is an outcomes-based offering for payers and employers designed to mitigate costs for diabetes-related complications. With this guarantee, Medtronic said it will provide flat-fee reimbursements of up to $25,000 per pump over four years for qualifying diabetes-related inpatient ho...
Source: MDDI - July 18, 2018 Category: Medical Devices Authors: Amanda Pedersen Tags: Business Source Type: news

Diabetes type 1 symptoms: Seven signs an adult has blood sugar problems
DIABETES type 1 symptoms may appear in adult life, not just at birth. The condition is caused by problems with the pancreas, which stops it producing the hormone to control blood sugar levels, insulin, which results in unexplained weight loss if not treated. This woman developed diabetes type 1 symptoms during adulthood. (Source: Daily Express - Health)
Source: Daily Express - Health - July 18, 2018 Category: Consumer Health News Source Type: news

Basal Insulin Analogues Similar for Glucose Lowering
WEDNESDAY, July 18, 2018 -- Basal insulin analogues for type 2 diabetes mellitus (T2DM) do not substantially differ in their glucose-lowering effect, according to a review published online July 10 in the Annals of Internal... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 18, 2018 Category: Pharmaceuticals Source Type: news

Diabetes symptoms: Seven warning signs you have the condition
DIABETES type 1 symptoms may appear in adult life, not just at birth. The condition is caused by problems with the pancreas, which stops it producing the hormone to control blood sugar levels, insulin, which results in unexplained weight loss if not treated. This woman developed diabetes type 1 symptoms during adulthood. (Source: Daily Express - Health)
Source: Daily Express - Health - July 18, 2018 Category: Consumer Health News Source Type: news

Diabetes symptoms: This change in your waistline could be a warning sign
DIABETES type 1 symptoms may appear in adult life, not just at birth. The condition is caused by problems with the pancreas, which stops it producing the hormone to control blood sugar levels, insulin, which results in unexplained weight loss if not treated. This woman developed diabetes type 1 symptoms during adulthood. (Source: Daily Express - Health)
Source: Daily Express - Health - July 18, 2018 Category: Consumer Health News Source Type: news

Diabetes type 1 symptoms: This woman lost 10 kg in a week before being diagnosed
DIABETES type 1 symptoms may appear in adult life, not just at birth. The condition is caused by problems with the pancreas, which stops it producing the hormone to control blood sugar levels, insulin, which results in unexplained weight loss if not treated. This woman developed diabetes type 1 symptoms during adulthood. (Source: Daily Express - Health)
Source: Daily Express - Health - July 18, 2018 Category: Consumer Health News Source Type: news

Diabetes type 1 symptoms: Unexplained weight loss? This woman lost 10 kg before diagnosis
DIABETES type 1 symptoms may appear in adult life, not just at birth. The condition is caused by problems with the pancreas, which stops it producing the hormone to control blood sugar levels, insulin, which results in unexplained weight loss if not treated. This woman developed diabetes type 1 symptoms during adulthood. (Source: Daily Express - Health)
Source: Daily Express - Health - July 18, 2018 Category: Consumer Health News Source Type: news

Little Difference Between Basal Insulin Analogs for Type 2 Diabetes Little Difference Between Basal Insulin Analogs for Type 2 Diabetes
Evidence comparing old versus new insulin analogs is poor quality. There are'many options'and'high price tags'but'little ability to discern the potential benefits of one...versus another,'said one commentator.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 17, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Deadly Respiratory Distress Mimic
Medic 534, staffed by a paramedic and EMT, is dispatched to a nursing home for a 78-year-old female in respiratory distress. On arrival, the crew finds the patient in a chair accompanied by two nurses and the administrator on call. The patient is in obvious distress showing fatigue and an increased work of breathing. She is alert to voice, but diaphoretic, lethargic, and unable to speak due to rapid, shallow breathing. A nurse is administering a nebulizer containing 3 mL of albuterol sulfate/ipratropium. A second nurse states that the patient has been in increasing distress for the last 45 minutes. The nurse also says that...
Source: JEMS Patient Care - July 17, 2018 Category: Emergency Medicine Authors: Brenton Faber, PhD, NRP Tags: Airway & Respiratory Patient Care Source Type: news

CeQur acquires wearable insulin delivery device
CeQur said today that it acquired a wearable, on-demand insulin delivery system from Johnson & Johnson‘s (NYSE:JNJ) Calibra Medical for an undisclosed amount. The Calibra device is designed to dose rapid-acting, mealtime insulin for people with Type II diabetes. In a 278-person study, use of the Calibra device resulted in higher ease-of-use and patient satisfaction scores, as well as less glycemic variability compared to insulin injection pens. Get the full story at our sister site, Drug Delivery Business News. The post CeQur acquires wearable insulin delivery device appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - July 17, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations Mergers & Acquisitions Pharmaceuticals Calibra Medical Inc. CeQur Ltd. johnsonandjohnson Source Type: news

Marlborough's CeQur revives expansion plans after buying J & J insulin device
CeQur CEO Bob Farra said the company plans to boost headcount with the addition of OneTouch, a wearable insulin delivery system. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - July 17, 2018 Category: Pharmaceuticals Authors: Allison DeAngelis Source Type: news

CeQur acquires Johnson & Johnson's Calibra insulin delivery patch
As Johnson& Johnson continues to move out of the diabetes business, the company has sold its Calibra product (marketed as OneTouch Via, but never launched) to CeQur, a 10-year-old company working on a similar insulin-delivery wearable. Terms of the deal were not disclosed, but CeQur has acquired an exclusive worldwide license for the technology. (Source: mobihealthnews)
Source: mobihealthnews - July 17, 2018 Category: Information Technology Source Type: news

Protective liquid enables oral insulin delivery in rats
Researchers developed a way to package insulin into pills that lowered blood sugar safely in rats. The approach could lead to an oral insulin option for people with diabetes. (Source: NIH Research Matters from the National Institutes of Health (NIH))
Source: NIH Research Matters from the National Institutes of Health (NIH) - July 17, 2018 Category: Consumer Health News Source Type: news

UAB researchers make big discovery on diabetes research
Researchers at the UAB ’s comprehensive Diabetes Center have discovered a safe and effective therapy to reduce insulin requirements and hypoglycemic episodes in adult subjects with recent onset Type 1 diabetes by promoting the patient’s own beta cell function and insulin production – the first such discovery to targ et diabetes in this way.  The findings reveal that regular oral application of verapamil, a common blood pressure medication, also enabled patients to produce higher levels of their… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 16, 2018 Category: Biotechnology Authors: Tyler Patchen Source Type: news

UAB researchers make big discovery on diabetes research
Researchers at the UAB ’s comprehensive Diabetes Center have discovered a safe and effective therapy to reduce insulin requirements and hypoglycemic episodes in adult subjects with recent onset Type 1 diabetes by promoting the patient’s own beta cell function and insulin production – the first such discovery to targ et diabetes in this way.  The findings reveal that regular oral application of verapamil, a common blood pressure medication, also enabled patients to produce higher levels of their… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - July 16, 2018 Category: American Health Authors: Tyler Patchen Source Type: news

Diabetes: Eat 10 jelly beans to help maintain blood sugar levels
DIABETES type 1 tends to be detected shortly after birth, and is caused by problems with the production of insulin. Sufferers need to be careful to ensure blood sugar levels don ’t get too high or too low, hypoglycaemia, which can both be life-threatening. If blood sugar levels are low, eating this could help raise them. (Source: Daily Express - Health)
Source: Daily Express - Health - July 15, 2018 Category: Consumer Health News Source Type: news

Diabetes: Eating 10 jelly beans could help you maintain blood sugar levels
DIABETES type 1 tends to be detected shortly after birth, and is caused by problems with the production of insulin. Sufferers need to be careful to ensure blood sugar levels don ’t get too high or too low, hypoglycaemia, which can both be life-threatening. If blood sugar levels are low, eating this could help raise them. (Source: Daily Express - Health)
Source: Daily Express - Health - July 15, 2018 Category: Consumer Health News Source Type: news

Verapamil Success for T1D; Bariatric Surgery Wait; Self-Monitoring Without Insulin?
(MedPage Today) -- News and commentary from the endocrinology world (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - July 13, 2018 Category: Cardiology Source Type: news

' Whatever It Takes': Helping Patients Afford Insulin'Whatever It Takes': Helping Patients Afford Insulin
Anne Peters and Irl Hirsch discuss alternatives to pricey analog insulins.Endocrine Society (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 13, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology Commentary Source Type: news

Insulet extends deal with Glooko in Europe
Insulet (NSDQ:PODD) said today that it inked a deal with Glooko to connect data from Insulet’s Omnipod insulin delivery devices in Europe with the Glooko+diasend diabetes data management system. Glooko touted that its data management tech is used at roughly 7,000 provider sites across 23 countries. The Glooko+diasend system allows users to sync and review data from an array of diabetes devices, giving them insights into their insulin regimen. Get the full story at our sister site, Drug Delivery Business News. The post Insulet extends deal with Glooko in Europe appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - July 13, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Big Data Diabetes Drug-Device Combinations Patient Monitoring Pharmaceuticals Wall Street Beat Glooko Insulet Source Type: news

Basal Insulin Analogs Don't Cut Hypoglycemia-Linked ER Visits
THURSDAY, July 12, 2018 -- Initiation of a basal insulin analog versus human neutral protamine Hagedorn (NPH) insulin is not associated with reduction in the risk of hypoglycemia-related emergency department visits or hospital admissions, according... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 12, 2018 Category: Pharmaceuticals Source Type: news

Powdered insulin to prevent type-1 diabetes in children
A new clinical trial will investigate if giving powdered insulin to babies at high risk of developing type-1 diabetes can be a solution to prevent the disease.BBC News (Source: Society for Endocrinology)
Source: Society for Endocrinology - July 12, 2018 Category: Endocrinology Source Type: news

TB vaccine shows promise against diabetes
For Hodalis Gaytan, 20, living with Type 1 diabetes means depending on an assortment of expensive medicines and devices to stay healthy. Test strips. Needles. A glucose meter. Insulin. (Source: CNN.com - Health)
Source: CNN.com - Health - July 12, 2018 Category: Consumer Health News Source Type: news

Medical News Today: Type 2 diabetes, obesity may soon be reversed with gene therapy
For the first time, scientists use gene therapy to successfully reverse obesity and insulin resistance in an animal model of type 2 diabetes. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 12, 2018 Category: Consumer Health News Tags: Diabetes Type 2 Source Type: news

Single injection could cure both obesity and type 2 diabetes
Researchers from the  Autonomous University of Barcelona found that injecting a hormone, known as FGF21, causes weight loss and greater insulin sensitivity in rodents. (Source: the Mail online | Health)
Source: the Mail online | Health - July 11, 2018 Category: Consumer Health News Source Type: news

Guess What Alphabet ’s Verily is Up to Now
Verily Life Sciences has formed yet another joint venture with a medtech company. This time Verily, once known as Google’s life sciences division, is teaming up with sleep-health specialist ResMed to tackle sleep apnea. The collaboration with ResMed expands the Mountain View, CA-based company’s presence into yet another healthcare segment. ResMed executives declined to discuss specific details about the joint venture, noting it was still subject to regulatory approvals. However, ResMed CMO Carlos Nunez said the joint venture will operate as a completely separate entity from ResMed and Verily. Nunez noted ResMed...
Source: MDDI - July 11, 2018 Category: Medical Devices Authors: Omar Ford Tags: Business Digital Health Source Type: news

Guess What Google ’s Verily is Up to Now
Verily Life Sciences has formed yet another joint venture with a medtech company. This time Verily, once known as Google’s life sciences division, is teaming up with sleep-health specialist ResMed to tackle sleep apnea. The collaboration with ResMed expands the Mountain View, CA-based company’s presence into yet another healthcare segment. ResMed executives declined to discuss specific details about the joint venture, noting it was still subject to regulatory approvals. However, ResMed CMO Carlos Nunez said the joint venture will operate as a completely separate entity from ResMed and Verily. Nunez noted ResMed...
Source: MDDI - July 11, 2018 Category: Medical Devices Authors: Omar Ford Tags: Business Digital Health Source Type: news

Medtronic & #039;s Value-Based Partnerships are Paying Off in Spades
Dublin, Ireland-based Medtronic continues to lead the charge toward value-based care, and it's beginning to pay off in a big way.  One of the company's value-based care partners, UnitedHealthcare, has seen a 27% decline in the rate of preventable hospital admissions for Medtronic insulin pump users compared to patients on multiple daily insulin injections, according to an analysis of more than 6,000 members with diabetes on Medtronic MiniMed 630G and previous generation insulin pumps. And that's just in the first year of the partnership. The analysis included a mix of members using both standalone insulin pumps and pu...
Source: MDDI - July 11, 2018 Category: Medical Devices Authors: Amanda Pedersen Tags: Business Source Type: news

Following 2016 deal, UnitedHealthcare members using Medtronic insulin pumps saw fewer avoidable hospital admissions
In 2016, UnitedHealthcare and Medtronic cut a deal that established the latter ’s devices as the preferred insulin pumps for United members with diabetes. (Source: mobihealthnews)
Source: mobihealthnews - July 11, 2018 Category: Information Technology Source Type: news

NHS to screen newborns in search for a type 1 diabetes cure
Feeding babies powdered insulin could stop them ever developing type 1 diabetes, according to scientists who are beginning an NHS screening programme in England's Thames Valley. (Source: the Mail online | Health)
Source: the Mail online | Health - July 11, 2018 Category: Consumer Health News Source Type: news

Single injection could cure both obesity AND type 2 diabetes without any side effects, study finds
Researchers from the  Autonomous University of Barcelona found that injecting a hormone, known as FGF21, causes weight loss and greater insulin sensitivity in rodents. (Source: the Mail online | Health)
Source: the Mail online | Health - July 11, 2018 Category: Consumer Health News Source Type: news

NHS to screen newborns in search for a type 1 diabetes cure
Feeding babies powdered insulin could stop them ever developing type 1 diabetes, according to scientists who are beginning an NHS screening programme in England's Thames Valley. (Source: the Mail online | Health)
Source: the Mail online | Health - July 11, 2018 Category: Consumer Health News Source Type: news

Hope for type 1 diabetes cure as feeding babies powdered insulin could stop the condition developing
Feeding babies powdered insulin could stop them ever developing type 1 diabetes, according to scientists who are beginning an NHS screening programme in England's Thames Valley. (Source: the Mail online | Health)
Source: the Mail online | Health - July 11, 2018 Category: Consumer Health News Source Type: news

Circadian System, Misalignment Have Distinct Impact on Insulin
WEDNESDAY, July 11, 2018 -- The endogenous circadian system, behavioral cycle, and circadian misalignment have distinct effects on insulin sensitivity and β-cell function, according to a study published online June 4 in Diabetes, Obesity and... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 11, 2018 Category: Pharmaceuticals Source Type: news

Medtronic touts one-year data from insulin pump study
Medtronic (NYSE:MDT) and UnitedHealthcare (NYSE:UNH) today touted first-year results from a 6,000-person analysis designed to compare hospital admission rates between people with diabetes using insulin pumps and people controlling their diabetes with multiple daily injections of insulin. The study included people using Medtronic’s MiniMed 630G system, as well as previous iterations of the medtech giant’s insulin pumps. Get the full story at our sister site, Drug Delivery Business News. The post Medtronic touts one-year data from insulin pump study appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - July 10, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Diabetes Drug-Device Combinations Pharmaceuticals Wall Street Beat Medtronic UnitedHealthcare Source Type: news

Diabetes type 2: Low-carb diet can ‘absolutely’ reverse condition and control blood sugar
DIABETES type 2 happens when the body can no longer control blood sugar levels due to problems with the hormone insulin. Although seeming like a life-sentence, it is ‘absolutely’ possible to reverse the condition with the low-carb diet according to an expert with more than 20 years experience. (Source: Daily Express - Health)
Source: Daily Express - Health - July 10, 2018 Category: Consumer Health News Source Type: news

Eversense Buzz Continues with New Collaboration
Two powerhouses in the diabetes treatment and management space are in a new collaboration. Senseonics, which has been buzzing since receiving a PMA for the Eversense continuous glucose monitoring CGM system in June, and Glooko have announced a new agreement. The partnership enables integration of the long-term Eversense branded CGM systems with Glooko’s diabetes data management platform. The integration of these solutions will allow Eversense CGM data to be synced into Mountain View, CA-based Glooko’s platform directly from the Germantown, MD -based Senseonics cloud. The companies said that Eversense users will...
Source: MDDI - July 10, 2018 Category: Medical Devices Authors: Omar Ford Tags: Digital Health Business Source Type: news

Standard type 2 diabetes treatments may not improve the condition in youth
Taking insulin or the most commonly used drug for type 2 diabetes, metformin, failed to either delay or effectively treat the condition in youth. (Source: Yale Science and Health News)
Source: Yale Science and Health News - July 10, 2018 Category: Universities & Medical Training Source Type: news

Gene therapy successfully reverts obesity and type-2 diabetes
According to a new study inEMBO Molecular Medicine, a single administration of a viral vector to mouse models of obesity can induce weight loss and decrease insulin resistance.Medical Xpress (Source: Society for Endocrinology)
Source: Society for Endocrinology - July 10, 2018 Category: Endocrinology Source Type: news

New technology for early detection of type 1 diabetes
(RMIT University) By the time a child is diagnosed with type 1 diabetes, about 70 percent of their insulin-producing cells have already been destroyed. New technology is being developed to accurately predict if a child is at risk, with the ultimate aim of a detection kit that could be used as a standard test for newborns. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 10, 2018 Category: International Medicine & Public Health Source Type: news

HbA1c Reduction Similar in Old, New Basal Insulin Analogues
(MedPage Today) -- Most notable differences seen with weight gain (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - July 9, 2018 Category: Cardiology Source Type: news

Gene therapy used to control diabetes, reduce obesity in mice
In one administration of gene therapy, researchers caused weight loss in mice and lowered insulin resistance, curing obesity and type 2 diabetes in the rodents. (Source: Health News - UPI.com)
Source: Health News - UPI.com - July 9, 2018 Category: Consumer Health News Source Type: news

Liraglutide: A New Player in Type 1 Diabetes Treatment? Liraglutide: A New Player in Type 1 Diabetes Treatment?
In a randomized, placebo-controlled trial, liraglutide added to insulin improved glycemic control and reduced weight and blood pressure.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 9, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Companion Medical wins FDA nod for Android version of smart pen app
Companion Medical said today that it won FDA clearance for the Android version of its InPen app. The company’s InPen system consists of a smart insulin injection pen that connects with an integrated diabetes management app. Companion Medical expects to release the app for Android users by the fourth quarter of this year. Get the full story at our sister site, Drug Delivery Business News. The post Companion Medical wins FDA nod for Android version of smart pen app appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - July 9, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Regulatory/Compliance Wall Street Beat Companion Medical Source Type: news

Human clinical trial reveals verapamil as an effective type 1 diabetes therapy
Researchers at the University of Alabama at Birmingham Comprehensive Diabetes Center have discovered a safe and effective novel therapy to reduce insulin requirements and hypoglycemic episodes in adult subjects with recent onset Type 1 diabetes by promoting the patient's own beta cell function and insulin production - the first such discovery to target diabetes in this manner. (Source: World Pharma News)
Source: World Pharma News - July 9, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Diabetes type 2: Can low blood sugar levels cause you to sweat?
DIABETES type 2 occurs when the body can no longer control blood sugar levels due to problems with the hormone insulin. In the hot weather sweating may occur more frequently, but can it be caused by diabetes? (Source: Daily Express - Health)
Source: Daily Express - Health - July 9, 2018 Category: Consumer Health News Source Type: news